Intra-Cellular Therapies, Inc. (ITCI)

Market Cap	13.41B
Revenue (ttm)	613.73M
Net Income (ttm)	-86.37M
Shares Out	106.24M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,897,368
Open	126.65
Previous Close	126.26
Day's Range	126.16 - 126.74
52-Week Range	62.78 - 128.00
Beta	0.70
Analysts	Buy
Price Target	100.31 (-20.52%)
Earnings Date	Feb 20, 2025

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 610
• Stock Exchange: NASDAQ
• Ticker Symbol: ITCI

Financial Performance

In 2023, Intra-Cellular Therapies's revenue was $464.37 million, an increase of 85.51% compared to the previous year's $250.31 million. Losses were -$139.67 million, -45.49% less than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is $100.31, which is a decrease of -20.52% from the latest price.

Price Target

$100.31

(-20.52% downside)

Analyst Consensus: Buy